For use in the detection and identification of nuclear factor kappa B, they are ideal for use in western blotting, immunoprecipitation and immunohistochemistry
A new range of antibodies for use in the detection and identification of nuclear factor kappa B (NFkB), is now available from Cambridge BioScience.
These antibodies (NFkB p50, NFkB p52 and NFkB p65) are produced by Delta Biolabs and are ideal for use in western blotting, immunoprecipitation and immunohistochemistry.
Also, for a limited period, Cambridge BioScience is offering a free radio with all purchases from the Delta Biolabs antibody range.
Research into the function of NFkB is of major importance.
Recent studies have suggested that NFkB plays a role in the development of numerous pathological states. Activation of NFkB induces gene programmes leading to the transcription of factors that promote inflammation, such as leukocyte adhesion molecules, cytokines, and chemokines.
It is also thought that there are some substances with possible anti-inflammatory effects that are also NFkB regulated.
There is some evidence indicating NFkB as a key factor in the pathophysiology of cardiac ischemia-reperfusion injury as well as the development of insulin dependent Diabetes Mellitus.
Members of the rel/NFkB family of transcription factors are also involved in the regulation of cellular responses, such as growth, development, and the inflammatory response.
These products are available from Cambridge BioScience in the UK and Ireland only.
